Table of Contents
Chapter 1. Executive Summary
1.1. Overview of Biomanufacturing Shifts
1.2. Post-COVID Impacts and Future Outlook (2021-2033)
Chapter 2. Key Trend Themes
2.1. Rising Biologics Demand and Next-Gen Therapies
2.2. Vertical Integration and Platform Acquisitions
2.3. Regional Reshoring and Supply Chain Redundancy
Chapter 3. M&A Activities in the Biomanufacturing Sector
3.1. Overview of Recent Strategic Deals (2021-2025)
3.2. Key Acquisitions by CDMOs and Biopharma Players, with mapping of modalities
Chapter 4. Global Capacity Expansion Highlights (2021-2025)
4.1. Greenfield Projects and Technology-Focused Investments
4.2. Single-Use, Modular, and Multi-Modality Manufacturing
4.3. Case Examples: Samsung Biologics, WuXi, Fujifilm Diosynth
Chapter 5. Regional Biomanufacturing Capacity Analysis
5.1. North America: Innovation and Advanced Therapy Hubs
5.2. Europe: Regulatory Stability and Skilled Workforce
5.3. Asia-Pacific: Cost Efficiency and Government Support
5.4. RoW
Chapter 6. Technology Focus Areas
6.1. mRNA, Cell/Gene Therapy, Single-Use Systems
6.2. Digitalization and AI-Driven Biomanufacturing